We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Viracta closes Series C; new partner Salubris participates
06 Dec 2018
Executive Summary
Viracta Therapeutics Inc. closed its Series C round, led by a $10mm investment from new partner Shenzhen Salubris Pharmaceuticals Co. Ltd. Returning backers NantKwest, Latterell Venture Partners, and Forward Ventures also participated. Viracta is developing treatments for viral-related cancers, and concurrent with the Series C round, granted Salubris exclusive rights to develop and sell its lead candidate nanatinostat/valganciclovir in China for Epstein Barr virus-associated lymphomas, solid tumors, and for the prevention of EBV-associated post-transplant lymphoproliferative disorder. The project is currently in Phase Ib/II trials.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?